TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00227617
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.
Study: NCT00227617
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg/m2 IV q 2 wk on day 1 over a 2-hour period
Study: NCT02259738
Drug: Human Urinary Kallidinogenase
Normalized name: kallidinogenase
DrugBank: Kallidinogenase (DB13197)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03943784
Drug: Non-Selective Beta-Blocking Agent
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients of the Propranolol group that presented medium to large esophageal varices without contraindication to Non-Selective Beta-Blockers, received propranolol, 1 mg/Kg/day every 8 hours, titrated to reduce the basal heart rate in 25% and not exceeding 5 mg/Kg/day. Patients were evaluated monthly until this reduction in heart rate was achieved, and every three to six months thereafter.
Study: NCT04370925
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy regimens: CapeOx and mFOLFOX6 are preferred for stage Ⅲ patients.~CapeOx:oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~mFOLFOX6:oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~For stageⅡpatiens, regimens recommend by NCCN guide line(2019 v1) are acceptable.
Study: NCT04475432
Drug: TP-03 Vehicle
Normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vehicle of TP-03 ophthalmic solution, administered twice a day
Study: NCT03611556
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive IV infusion of nab-paclitaxel as stated in arm description.
Study: NCT03427684
Drug: S1
Normalized name: LS11
DrugBank: LS11 (DB05918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 80mg/m2/day, orally intake on radiotherapy days.
Study: NCT03611556
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive IV infusion of oxaliplatin as stated in arm description.
Study: NCT03611556
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive IV infusion of folinic acid as stated in arm description.
Study: NCT03611556
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive IV infusion of 5-FU as stated in arm description.
Study: NCT05142449
Drug: Amoxilan
Normalized name: Ioxilan
DrugBank: Ioxilan (DB09135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive 8 capsules Amoxilan perioperatively and for the next 3 days 6 capsules per day
Study: NCT01683084
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00457470
Drug: AG-014699
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00248378
Drug: Smoked Cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02440633
Drug: 14C-OPS-2071
Normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will swallow Single 25 mL of suspension containing 50 mg of 14C-OPS-2071 directly.
Study: NCT00579280
Drug: divalproex sodium ER
Normalized name: Divalproex Sodium ER
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible dosing, 500 mg up to a maximum of 3000 mg per day for 8 weeks
Study: NCT02397707
Drug: Voxilaprevir
Normalized name: Voxilaprevir
DrugBank: Voxilaprevir (DB12026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg tablet administered orally
Study: NCT02157948
Drug: Denosumab (CP2)
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab produced by a process referred to as CP2, administered subcutaneously from a prefilled syringe.
Study: NCT01679561
Drug: intralipid
Normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous intralipid 20% is given to the patients known to be have either recurrent failed IVF, RPL
Study: NCT02157948
Drug: Denosumab (CP4)
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab produced by a process referred to as CP4, administered subcutaneously from a prefilled syringe.
Study: NCT00142246
Drug: Intermittent preventive treatment (SP and amodiaquine)
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral medication. SP: single dose given over one day; amodiaquine: 3 daily doses over 3 days. Dosage has given according to age.
Study: NCT00399685
Drug: Ortho Tri-Cyclen LO
Normalized name: Ortho Tri-Cyclen Lo
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, oral, OTC Lo 1 tab/daily (no dosage units), once daily, 28 days.
Study: NCT00399685
Drug: Ortho Cyclen
Normalized name: Ortho Cyclen
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, oral, Ortho Cyclen 1 tab/daily (no dosage units), once daily, 28 days.
Study: NCT00399685
Drug: Ortho Cyclen + Efavirenz
Normalized name: norgestimate
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, oral, OC + EFV 600 mg, once daily, 14 days.
Study: NCT01634945
Drug: SP/amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =\< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =\< 10 kg), every three months, i.e. 3 times during 9 consecutive months.
Study: NCT01634945
Drug: SP/Amodiaquine + FeFum fortified porridge
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =\< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =\< 10 kg), every three months, i.e. 3 times during 9 consecutive months.~6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months.
Study: NCT00399685
Drug: Ortho Cyclen
Normalized name: Ortho Cyclen
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, oral, OC 1 tab daily (no dosage units), once daily, 7 days.
Study: NCT01524497
Drug: Trazodone
Normalized name: Trazodone
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg tablet/150 mg tablet
Study: NCT01276275
Drug: Risk of selected safety events
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First time users of ticagrelor, clopidogrel and prasugrel, respectively
Study: NCT02852824
Drug: BI 655130 (spesolimab)
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04780945
Drug: Olaparib Oral Product
Normalized name: olaparib Oral Product
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg bid
Study: NCT00999336
Drug: Betrixaban
Normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg betrixaban qd for 8 days
Study: NCT01012063
Drug: iron sucrose, erythropoietin-β
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 200 mg of iron sucrose diluted with 100 ml of normal saline was given intravenously over one hour and the 3000 IU of Epo-β was injected subcutaneously.
Study: NCT00211549
Drug: IDEA-033
Normalized name: ALUMINUM ZIRCONIUM OCTACHLOROHYDREX GLY 16.4 g in 100 g TOPICAL GEL [Dry Idea Antiperspirant]
DrugBank: Aluminum zirconium octachlorohydrex gly (DB11200)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00406887
Drug: Difluprednate Ophthalmic Emulsion
Normalized name: Difluprednate Ophthalmic Emulsion
DrugBank: Difluprednate (DB06781)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00968903
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 125 mg iv pre-operatively
Study: NCT00881296
Drug: gemcitabine and carboplatin
Normalized name: Carboplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000mg/m2, DIV on day 1 and 15 of each 28 day cycle. Carboplatin AUC=3, DIV on day 1 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles.
Study: NCT00881296
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000mg/m2, DIV on day 1, 8 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles
Study: NCT02101138
Drug: Dexpramipexole
Normalized name: Dexpramipexole
DrugBank: Dexpramipexole (DB15130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexpramipexole (KNS 760704) is a synthetic amino-benzothiazole developed for use in amyotrophic lateral sclerosis (ALS)
Study: NCT01706666
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT01706666
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01706666
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00002544
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002544
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01263496
Drug: Alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks.
Study: NCT01263496
Drug: Alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks.
Study: NCT01263496
Drug: Alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks.
Study: NCT01263496
Drug: Alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks.
Study: NCT01263496
Drug: Voglibose
Normalized name: Voglibose
DrugBank: Voglibose (DB04878)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
Study: NCT01376362
Drug: Interferon Gamma-1b
Normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
Study: NCT00968695
Drug: Albumin
Normalized name: Albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pattern of administration of 20% human albumin is 1.5g/kg every week to be infused in 6 hours with a minimum of 90g up and a maximum of 150g in patients weighing less than 60 kg and more than 100 kg, respectively. Treatment duration is 12 weeks, which are 13 administrations of albumin.
Study: NCT03395600
Drug: B1S5
Normalized name: Betamethasone Sodium Succinate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
Study: NCT03395600
Drug: B1S10
Normalized name: Betamethasone Sodium Phosphate and Betamethasone Acetate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 10µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
Study: NCT00266656
Drug: Humatrope
Normalized name: Humatrope
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to investigator's clinical practice and guided by the approved package insert
Study: NCT01650051
Drug: Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg
DrugBank: Phenazopyridine (DB01438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side.
Study: NCT01650051
Drug: Phenazopyridine Hydrochloride Tables, USP 200 mg
DrugBank: Phenazopyridine (DB01438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side.
Study: NCT01475110
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Observation of Imatinib resistant patients treated with Nilotinib.
Study: NCT03927651
Drug: ICG
Normalized name: ICG136
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indocyanine green (ICG) is a Food and Drug (FDA)-approved tricarbocyanine dye that is fluorescent under near-infrared (NIR) light. ICG solutions for injection often contain sodium iodide. ICG is water soluble and when introduced intravenously, it is bound by plasma proteins, namely albumin. The intravascular half-life of ICG is 3-4 minutes with rapid hepatic clearance.
Study: NCT02915783
Drug: lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 mg and 10 mg capsules
Study: NCT02915783
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg tablets
Study: NCT02241785
Drug: natalizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT02595346
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples.
Study: NCT00405158
Drug: cefadroxil
Normalized name: Cefadroxil
DrugBank: Cefadroxil (DB01140)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00405158
Drug: penicillin
Normalized name: Penicillin
DrugBank: Nafcillin (DB00607)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00405158
Drug: flucloxacillin
Normalized name: Flucloxacillin
DrugBank: Flucloxacillin (DB00301)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00116649
Drug: imiquimod cream
Normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: imiquimod 5% cream applied in doses ranging from one packet (12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for up to 3 cycles
Study: NCT02871661
Drug: Amitriptyline
Normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Volunteers will take 25 milligrams of this medication every day from their enrollment until completing eight weeks long.
Study: NCT01180231
Drug: Moxonidine (Physiotens)
Normalized name: moxonidine Oral Tablet [Physiotens]
DrugBank: Moxonidine (DB09242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be asked to take moxonidine, dosage to be determined prior to commencement by a medical doctor for 6 months duration.
Study: NCT01827982
Drug: JNJ-54861911 1mg
Normalized name: JNJ-54861911
DrugBank: Atabecestat (DB15307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-54861911 1 mg will be administered as a single oral dose after an overnight fast of at least 10 hours.
Study: NCT01827982
Drug: JNJ-54861911 3 mg
Normalized name: JNJ-54861911
DrugBank: Atabecestat (DB15307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-54861911 3 mg will be administered as a single oral dose.
Study: NCT01827982
Drug: JNJ-54861911 9 mg
Normalized name: JNJ-54861911
DrugBank: Atabecestat (DB15307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-54861911 9 mg will be administered as a single oral dose.
Study: NCT01827982
Drug: JNJ-54861911 27 mg
Normalized name: JNJ-54861911
DrugBank: Atabecestat (DB15307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-54861911 27 mg will be administered as a single oral dose.
Study: NCT01827982
Drug: JNJ-54861911 81 mg
Normalized name: JNJ-54861911
DrugBank: Atabecestat (DB15307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-54861911 81 mg will be administered as a single oral dose.
Study: NCT01827982
Drug: JNJ-54861911 160 mg
Normalized name: JNJ-54861911
DrugBank: Atabecestat (DB15307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-54861911 160 mg will be administered as a single oral dose.
Study: NCT01827982
Drug: JNJ-54861911 tbd
Normalized name: TBD
DrugBank: 2,2-bis(4-hydroxy-3-tert-butylphenyl)propane (DB13008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of JNJ-54861911 will be derived from the results obtained in Parts 1 and 2.
Study: NCT01827982
Drug: JNJ-54861911 9 mg
Normalized name: JNJ-54861911
DrugBank: Atabecestat (DB15307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug will be administered after an overnight fast of at least 10 hours and within 120 minutes after placement of the spinal catheter.
Study: NCT03951259
Drug: SM934
Normalized name: Sodium Stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.
Study: NCT03258866
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22)
Study: NCT03258866
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: given with a single dose of 375mg/m2
Study: NCT00659126
Drug: Ferumoxytol
Normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00659126
Drug: Gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00031486
Drug: Valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valacyclovir is a L-valyl ester of acyclovir. Valacyclovir is provided in 500 mg tablets, 4 tablets (500 mg tablets) 3 times a day (every 8 hours) for 90 days.
Study: NCT03685591
Drug: PF-06952229
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 7 days on / 7 days off - 28 day cycles (Part 1)
Study: NCT03685591
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostate Cancer (Part 2). 160mg, capsules, orally, daily
Study: NCT00281710
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02600494
Drug: ITI-007 (Lumateperone)
Normalized name: Arthur Itis
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00760149
Drug: Rifampicin in higher doses
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)
Study: NCT01172002
Drug: Leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide, 20 mg/d, ORAL ,each day. Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks.
Study: NCT01269047
Drug: Pramlintide
Normalized name: Pramlintide
DrugBank: Pramlintide (DB01278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start at 15 mcg capped at 60 mcg before breakfast and supper subcutaneously for 4 months
Study: NCT01269047
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start at 1.25 mcg, capped at 5 mcg, subcutaneously, before breakfast and supper for 4 months
Study: NCT01269047
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rapid acting and long acting, subcutaneously, according to their regimen for the entire duration of the study.
Study: NCT03477266
Drug: Mosapride
Normalized name: mosapride
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intake mouthly dissolving mosapride tablets in immediate post cesarean section
Study: NCT03009344
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tazemetostat tablets.
Study: NCT03560271
Drug: Cyclo-Z
Normalized name: Z-160
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclo (His-Pro) and zinc
Study: NCT02819999
Drug: Rovalpituzumab Tesirine
Normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
Study: NCT02819999
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no